Mainz Biomed director reports equity holdings

Mainz Biomed N.V. director Hans Hekland reported his existing equity interests with no buy or sell transactions.

Accepted by SEC EDGAR 02/19/2026 - 05:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Mainz Biomed N.V. director Hans Hekland reported his existing equity interests with no buy or sell transactions. He directly holds 45,000 Ordinary Shares and several Employee Stock Options (Right to Buy), including positions with 10,000, 625, 250 and 125 underlying shares following the reported holdings.

One option grant vested 50% on 03/04/2025, with the remaining 25% tranches scheduled to vest on 03/24/2026 and 03/04/2027, while another option position is fully vested.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Hekland Hans

Role Director

Type	Security	Shares	Price	Value
Holding	Employee Stock Option (Right to Buy)	--	--	--
Holding	Employee Stock Option (Right to Buy)	--	--	--
Holding	Employee Stock Option (Right to Buy)	--	--	--
Holding	Employee Stock Option (Right to Buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Employee Stock Option (Right to Buy) — 11,000 contracts (Direct); Ordinary Shares — 45,000 shares (Direct)

Footnotes (2)

1. F1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
2. F2. Fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position is reported for Mainz Biomed (MYNZ)?

The filing shows Hans Hekland as a director of Mainz Biomed N.V.. It details his direct holdings in Ordinary Shares and Employee Stock Options, without indicating any purchase or sale transactions in the reported data.

How many Mainz Biomed (MYNZ) Ordinary Shares does Hans Hekland hold?

Hans Hekland directly holds 45,000 Ordinary Shares of Mainz Biomed N.V. This reflects his share ownership after the reported transactions, which are classified as holdings rather than explicit buys or sells.

What stock option holdings does Hans Hekland report in MYNZ?

He reports several Employee Stock Option (Right to Buy) positions, with post-transaction totals including 10,000, 625, 250 and 125 underlying shares. All are categorized as direct holdings in the filing data.

Is there a vesting schedule disclosed for Hans Hekland’s MYNZ options?

Yes. One option grant vested 50% on 03/04/2025, with the remaining balance vesting 25% on 03/24/2026 and 25% on 03/04/2027. Another option position is described as fully vested.

Does the Hans Hekland MYNZ filing show any share purchases or sales?

No explicit purchases or sales are identified. All entries are labeled as holding transactions with an unknown transaction code, indicating disclosure of existing positions rather than new buy or sell activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hekland Hans

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ 55129

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	45,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	03/04/2025	(1)	Ordinary Shares	10,000	$4.95	D
Employee Stock Option (Right to Buy)	01/26/2022	(2)	Ordinary Shares	125	$580	D
Employee Stock Option (Right to Buy)	11/04/2021	(2)	Ordinary Shares	625	$200	D
Employee Stock Option (Right to Buy)	12/21/2022	(2)	Ordinary Shares	250	$302.8	D

Explanation of Responses:

1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.

2. Fully vested.

	/s/ Hans Hekland	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.